StockData
NeuroPace Inc logo

NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3025% above fair value
$8.20+0.23 (+2.89%)

Close on Nov 17, 2026Market cap $281.46MP/E –Yield 0.00%

NeuroPace profit margin

Profit margin (net margin) is net income as a percentage of revenue.

NeuroPace's profit margin for the twelve months ending Jun 30, 2026 was -19.3%. For fiscal 2025 it was -21.5%, against -34.0% the year before. The highest annual figure on record is -21.5% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-21.5%+12.5
FY2024Dec 31, 2024-34.0%+16.4
FY2023Dec 31, 2023-50.4%+53.1
FY2022Dec 31, 2022-103.4%−23.6
FY2021Dec 31, 2021-79.9%−20.8
FY2020Dec 31, 2020-59.0%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-27.2%+17.2
Q1 FY2026Mar 31, 2026-30.3%−1.1
Q4 FY2025Dec 31, 2025-10.3%+14.2
Q3 FY2025Sep 30, 2025-12.8%+13.1
Q2 FY2025Jun 30, 2025-44.4%−5.3
Q1 FY2025Mar 31, 2025-29.3%+20.0
Q4 FY2024Dec 31, 2024-24.5%+10.0
Q3 FY2024Sep 30, 2024-25.9%+18.3
Q2 FY2024Jun 30, 2024-39.0%+16.2
Q1 FY2024Mar 31, 2024-49.2%+22.4
Q4 FY2023Dec 31, 2023-34.4%+52.7
Q3 FY2023Sep 30, 2023-44.2%+61.5
Q2 FY2023Jun 30, 2023-55.3%+69.1
Q1 FY2023Mar 31, 2023-71.7%+29.1
Q4 FY2022Dec 31, 2022-87.2%+10.1
Q3 FY2022Sep 30, 2022-105.6%−27.4
Q2 FY2022Jun 30, 2022-124.4%−57.2
Q1 FY2022Mar 31, 2022-100.8%−22.2
Q4 FY2021Dec 31, 2021-97.2%−54.3
Q3 FY2021Sep 30, 2021-78.2%−45.9
Q2 FY2021Jun 30, 2021-67.3%+47.8
Q1 FY2021Mar 31, 2021-78.5%−11.0
Q4 FY2020Dec 31, 2020-43.0%–
Q3 FY2020Sep 30, 2020-32.3%–
Q2 FY2020Jun 30, 2020-115.1%–
Q1 FY2020Mar 31, 2020-67.6%–

More NeuroPace figures

See a number that looks wrong?